Role of tear vasoactive intestinal peptide on dry eyes after laser keratorefractive surgery

What Was Tested

This clinical trial paper looks at VIP (Vasoactive Intestinal Peptide).

To explore the changes in vasoactive intestinal peptide (VIP) concentration in tears post laser-assisted sub-epithelial keratomileusis (LASEK) and femtosecond laser-assisted in situ keratomileusis (FS-LASIK) surgeries and related factors, possible association between postoperative dry eye symptoms and VIP concentration in tears, and factors influencing dry eye symptoms after different periods post LASEK and FS-LASIK surgeries.

The trial registration number: 2021JS22.

Who Took Part

According to the abstract, 23 subjects were involved.

In this prospective, non-randomized, longitudinal cohort study, 23 and 22 subjects were recruited and underwent LASEK and FS-LASIK, respectively.

After conducting an intact ophthalmic examination and collecting relevant surgical data, all subjects were examined for VIP concentration in their tears using ELISAs, tear-film breakup time, ocular staining and ocular surface disease index questionnaire before surgery and 1 day, 1 week, and 1 month post-surgery.

What Was Measured

To explore the changes in vasoactive intestinal peptide (VIP) concentration in tears post laser-assisted sub-epithelial keratomileusis (LASEK) and femtosecond laser-assisted in situ keratomileusis (FS-LASIK) surgeries and related factors, possible association between postoperative dry eye symptoms and VIP concentration in tears, and factors influencing dry eye symptoms after different periods post LASEK and FS-LASIK surgeries.

The subject headings attached to it are Cornea, Dry Eye Syndromes, Keratomileusis, Laser In Situ, Lacerations, Lasers, Excimer, Longitudinal Studies and Myopia.

Author keywords: Corneal ablation depth, FS-LASIK, LASEK and Vasoactive intestinal peptide.

What This Means in Plain Language

This is a clinical trial of VIP (Vasoactive Intestinal Peptide) in 23 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2023 (BMC ophthalmology), a journal based in England.

More context: the VIP (Vasoactive Intestinal Peptide) compound page, all human trials.